Cleared Traditional

WINK-EASE PERSONAL PROTECTIVE EYEWEAR (K873662) - FDA 510(k) Clearance

Class I Ophthalmic device.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 1987
Decision
22d
Days
Class 1
Risk

K873662 is an FDA 510(k) clearance for the WINK-EASE PERSONAL PROTECTIVE EYEWEAR. Classified as Shield, Eye, Ophthalmic (including Sunlamp Protective Eyewear And Post-mydriatic Eyewear) (product code HOY), Class I - General Controls.

Submitted by Eye Pro Medical Products, Inc. (Indianapolis, US). The FDA issued a Cleared decision on October 2, 1987 after a review of 22 days - a notably fast clearance cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4750 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Eye Pro Medical Products, Inc. devices

Submission Details

510(k) Number K873662 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 10, 1987
Decision Date October 02, 1987
Days to Decision 22 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
88d faster than avg
Panel avg: 110d · This submission: 22d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code HOY Shield, Eye, Ophthalmic (including Sunlamp Protective Eyewear And Post-mydriatic Eyewear)
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 886.4750
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.